| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06465953 | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With… | Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) | Recruiting |
| NCT04164901 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma… | Grade 2 Glioma | Active, Not Recruiting |
| NCT03869892 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who… | Metastatic Colorectal Cancer | Active, Not Recruiting |
| NCT03173248 | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants… | Newly Diagnosed Acute Myeloid Leukemia (AML) | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06501625 | Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in… | Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Recruiting |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Non-small Cell Lung Cancer | Recruiting |
| NCT07227857 | A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related… | Epileptic Encephalopathy | Recruiting |
| NCT06478212 | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | IDH1-mutant Glioma | Active, Not Recruiting |
| Phase 1 | |||
| NCT02074839 | Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies… | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Recruiting |
| NCT02735083 | A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who… | Advanced Lymphoid Leukemia | Active, Not Recruiting |
| NCT05484622 | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1… | Astrocytoma | Active, Not Recruiting |
| NCT02632708 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy… | Newly Diagnosed Acute Myeloid Leukemia (AML) | Active, Not Recruiting |